This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q3 2025.
Report Scope
- The Q3 CRO Activity and Intel report offers insights into CRO and sponsor activity, clinical trial trends, and geographical performance across various therapeutic areas.
Reasons to Buy
This report will enable the user to answer the following questions:
- What are the trends by region, therapy area, sites by CROs for the past quarter?
- Who was the most active CRO in the past quarter?
- Who were the most active sponsors by market cap in the past quarter?
- What was the most widely studied therapy area in the past quarter vs. the previous year’s quarter?
- By region, who had the most clinical trials initiated in the past quarter?
- By region, what were the past quarter’s CRO invitations and appointments?
Table of Contents
- Introduction
- Global
- CRO and sponsor activity in Q3 2025
- Most-used CROs
- Most active large- and mega-cap sponsors
- Most active mid-cap sponsors
- Most active small-cap sponsors
- Clinical trials in oncology and CNS
- Therapeutic area breakdown of clinical trials initiated in Q3 2025 vs. Q3 2024
- Trials initiated in the 10 most active oncology indications in Q3 2025 vs. Q3 2024
- Trials initiated in the 10 most active CNS indications in Q3 2025 vs. Q3 2024
- Top 10 CROs by number of sites in Q3 2025
- North America
- Clinical trial activity in North America in Q3 2025
- Most active North American regions in Q3 2025 vs. Q3 2024
- Phase breakdown of trials initiated in North America in Q3 2025 vs. Q3 2024
- Therapeutic area breakdown of clinical trials initiated in North America in Q3 2025 vs. Q3 2024
- Top 10 trial sites by trials initiated in North America in Q3 2025
- Insights: CRO invites for sponsors based in North America
- Insights: CRO appointments for sponsors based in North America
- Europe
- Clinical trial activity in Europe in Q3 2025
- Most active European regions in Q3 2025 vs. Q3 2024
- Phase breakdown of trials initiated in Europe in Q3 2025 vs. Q3 2024
- Therapeutic area breakdown of clinical trials initiated in Europe in Q3 2025 vs. Q3 2024
- Top 10 trial sites by trials initiated in Europe in Q3 2025
- Insights: CRO invites for sponsors based in Europe
- Rest of the world
- Clinical trial activity in ROW in Q3 2025
- Most active regions in ROW in Q3 2025 vs. Q3 2024
- Phase breakdown of trials initiated in ROW in Q3 2025 vs. Q3 2024
- Therapeutic area breakdown of clinical trials initiated in ROW in Q3 2025 vs. Q3 2024
- Top 10 trial sites by trials initiated in ROW in Q3 2025
- Appendix
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- ICON
- Astrazeneca
- Akesobio
- CSPPC Pharmaceutical
- ImmunityBio
- Boryung
